Skip to main content
. Author manuscript; available in PMC: 2019 Mar 28.
Published in final edited form as: Fatigue. 2017 Jun 30;5(4):202–214. doi: 10.1080/21641846.2017.1343171

Table 3.

Adjusted incremental cost, effectiveness, and cost-effectiveness ratios

Intervention Incremental Cost
(95% CI)		 Incremental Utility
(95% CI)		 ICUR
ITT analysis, 12 month
TAU Reference Reference Reference
FSM −$64
(−208, 77)		 0.014
(−0.008, 0.036)		 FSM dominant
Complete-case analysis, 12 month
TAU Reference Reference Reference
FSM −$36
(−190, 97)		 0.025
(0.001, 0.049)		 FSM dominant

ITT=Intention-to-treat; TAU=Treatment as Usual; FSM=Home-Based Fatigue Self-Management; CI=Confidence Interval.

ICUR = Incremental Cost-Utility Ratio, in 2013 US dollars; ICUR = −4442 for intention-to-treat analysis and −1455 for complete-cases-only analysis. Because the magnitude of negative ICUR do not convey the same information as positive ICUR do, “FSM dominant” is reported to indicate that FSM is more effective at lower costs as compared to TAU.

Effectiveness and costs were obtained from multivariate regression models adjusting for the following baseline characteristics: age, gender, ethnicity, education, marital status, and employment status.